Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
NCT04701502Phase 2Completed
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms). Primary endpoints: Clinical Improvement at 21 days, Time to semirecover at 21 days and 2 more. Started Nov 2020; status: completed.
Beyond the preview
Go deeper on NCT04701502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701502.